- Home
- SM vs ACAD Comparison
SM vs ACAD Comparison
Compare SM & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SM
- ACAD
- Stock Information
- Founded
- SM 1908
- ACAD 1993
- Country
- SM United States
- ACAD United States
- Employees
- SM N/A
- ACAD N/A
- Industry
- SM Oil & Gas Production
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- SM Energy
- ACAD Health Care
- Exchange
- SM Nasdaq
- ACAD Nasdaq
- Market Cap
- SM 2.7B
- ACAD 2.5B
- IPO Year
- SM 1992
- ACAD 2004
- Fundamental
- Price
- SM $27.57
- ACAD $22.71
- Analyst Decision
- SM Buy
- ACAD Buy
- Analyst Count
- SM 11
- ACAD 16
- Target Price
- SM $41.60
- ACAD $27.00
- AVG Volume (30 Days)
- SM 2.0M
- ACAD 1.6M
- Earning Date
- SM 08-06-2025
- ACAD 08-05-2025
- Dividend Yield
- SM 2.92%
- ACAD N/A
- EPS Growth
- SM 11.97
- ACAD N/A
- EPS
- SM 7.14
- ACAD 1.37
- Revenue
- SM $2,847,233,000.00
- ACAD $996,283,000.00
- Revenue This Year
- SM $30.95
- ACAD $13.39
- Revenue Next Year
- SM $1.16
- ACAD $10.59
- P/E Ratio
- SM $3.86
- ACAD $16.65
- Revenue Growth
- SM 24.88
- ACAD 22.42
- 52 Week Low
- SM $19.67
- ACAD $13.40
- 52 Week High
- SM $50.20
- ACAD $25.23
- Technical
- Relative Strength Index (RSI)
- SM 63.70
- ACAD 66.04
- Support Level
- SM $26.85
- ACAD $21.35
- Resistance Level
- SM $28.70
- ACAD $22.69
- Average True Range (ATR)
- SM 1.19
- ACAD 0.76
- MACD
- SM 0.30
- ACAD -0.13
- Stochastic Oscillator
- SM 78.02
- ACAD 70.76
About SM SM Energy Company
SM Energy Co is an independent energy company engaged in the acquisition, exploration, development, and production of oil, gas, and NGLs in Texas and Utah. Its portfolio is comprised of assets in the Midland Basin of West Texas, the Maverick Basin of South Texas, and the Uinta Basin of northeastern Utah.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.